Nachrichten und Videos - JOHNSON & JOHNSON

Johnson & Johnson (NYSE: JNJ) today announced that, based on preliminary results, its previously announced offer to its shareholders to exchange their shares of Johnson & Johnson common stock for shares of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) common stock owned by Johnson & Johnson was oversubscribed. The exchange offer expired at 12:00 midnight, New York City time, at the end of the day on August 18, 2023. Under the terms of the exchange offer, 8.0324 shares of Kenvue common stock will be...

Thinking about trading options or stock in Meta Platforms, Rigetti Computing, Sea Ltd, Paysafe, or Johnson & Johnson? PR Newswire NEW YORK, Aug. 17, 2023 NEW YORK , Aug. 17, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for META, RGTI, SE, PSFE, and JNJ. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital...

Johnson & Johnson (NYSE: JNJ) today announced the final exchange ratio for its previously announced split-off exchange offer to Johnson & Johnson shareholders to exchange their shares of Johnson & Johnson for shares of common stock of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) currently held by Johnson & Johnson. For each share of Johnson & Johnson common stock that is validly tendered and not validly withdrawn by shareholders and that is accepted by Johnson & Johnson pursuant to the exchange...

Johnson & Johnson (NYSE: JNJ) will participate in the 2023 Wells Fargo Securities Healthcare Conference at the Encore Boston Harbor in Everett, MA on Thursday, September 7 th . Ashley McEvoy, EVP, Worldwide Chairman, MedTech along with executives from Abiomed will represent the Company in a session scheduled at 10:15 a.m. (Eastern Time). This conference call will be available to investors and other interested parties by visiting the Johnson & Johnson website at www.investor.jnj.com . A webcast...

Kenvue Inc. (NYSE: KVUE) («Kenvue») ha anunciado su intención de presentar en el día de la fecha un formulario S-4 de Declaración de Registro ante la Comisión de Bolsa y Valores (la «SEC») en relación con la oferta propuesta por Johnson & Johnson (NYSE: JNJ) de canjear hasta 1 533 830 450 acciones ordinarias de Kenvue de las que es titular, que representan el 80,1 % del total de acciones ordinarias de Kenvue en circulación, por acciones ordinarias de Johnson & Johnson en circulación....

Kenvue Inc. (NYSE: KVUE) (« Kenvue ») a annoncé son intention de déposer aujourd'hui un formulaire S-4 auprès de la Securities and Exchange Commission (la « SEC ») dans le cadre de l'offre proposée par Johnson & Johnson (NYSE : JNJ) visant à échanger jusqu'à 1 533 830 450 actions ordinaires de Kenvue qu'elle détient, représentant 80,1 % du total des actions ordinaires en circulation de Kenvue, contre des actions ordinaires de Johnson & Johnson. Dans ce contexte, les actionnaires de...

Kenvue Inc. (NYSE: KVUE) (“Kenvue”) announced that it intends to file a Form S-4 Registration Statement today with the Securities and Exchange Commission (the “SEC”) in connection with Johnson & Johnson’s (NYSE: JNJ) proposed offer to exchange up to 1,533,830,450 shares of Kenvue common stock that it owns, representing 80.1% of the total outstanding shares of Kenvue common stock, for outstanding shares of Johnson & Johnson common stock. In the exchange offer, Johnson & Johnson...

Johnson & Johnson (NYSE: JNJ) today announced its intention to split-off at least 80.1% of the shares of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) through an exchange offer. Kenvue, formerly Johnson & Johnson’s Consumer Health business, completed its initial public offering (“IPO”) in May 2023. Through the planned exchange offer, Johnson & Johnson shareholders can exchange all, some or none of their shares of Johnson & Johnson common stock for shares of Kenvue common stock, subject to the...

Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2023. “Our robust performance in the second quarter and first half of 2023 is a testament to the hard work and commitment of our colleagues around the world,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “We are entering the back half of the year from a position of strength with numerous catalysts, including becoming a two-sector company focused on Pharmaceutical and MedTech innovation.”...

Johnson & Johnson (NYSE: JNJ) will participate in the UBS MedTech, Tools and Genomics Summit on Tuesday, August 15 th , at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA. Celine Martin, Company Group Chairman Cardiovascular & Specialty Solutions Group (CSS), Anthony (Tony) Long, VP, Clinical Research, Medical Affairs, Preclinical Research and Jasmina Brooks, President Biosense Webster will represent the Company in a session scheduled at 2:00 pm (Eastern Time). This webcast...

Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Thursday, July 20 th to review second-quarter results. Joaquin Duato, Chairman of the Board and CEO, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible...

Protagonist Reports Positive Results from Phase 1 and Pre-clinical Studies of Oral Interleukin-23 Receptor Antagonist JNJ-2113 PR Newswire NEWARK, Calif., May 12, 2023 Data point to the potential of JNJ-2113 as a first-in-class drug candidate in multiple IL-23 driven-diseases NEWARK, Calif. , May 12, 2023 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") reported data from its collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical...

Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 44 th Annual Global Healthcare Conference on Tuesday, June 13 th , at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, CA. Biljana Naumovic, Worldwide Vice President, Oncology, and Peter Lebowitz, Global Therapeutic Head, Oncology, will represent the Company in a session scheduled at 4:20 p.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson...

Johnson & Johnson (NYSE: JNJ) and Kenvue Inc. (“Kenvue”), a wholly owned subsidiary of Johnson & Johnson, today announced the pricing of Kenvue’s upsized initial public offering (“IPO”) of 172,812,560 shares of Kenvue’s common stock at a price to the public of $22.00 per share. In addition, Kenvue has granted the underwriters a 30-day option to purchase up to an additional 25,921,884 shares of its common stock to cover over-allotments, if any. Kenvue’s common stock has been...

Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein 39 th Annual Strategic Decisions Conference on Wednesday, May 31 st , at the New York Hilton Midtown in New York. Joaquin Duato, Chairman of the Board and Chief Executive Officer will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com . A webcast replay will be available...

Johnson & Johnson (NYSE: JNJ) today announced that Kenvue Inc. (“Kenvue”), a wholly owned subsidiary of Johnson & Johnson comprising its Consumer Health Business, has launched a roadshow for the initial public offering (“IPO”) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is currently expected to be between $20.00 and...

Thinking about trading options or stock in NVIDIA, Airbnb, Johnson & Johnson, Tesla, or Microsoft? PR Newswire NEW YORK, April 18, 2023 NEW YORK , April 18, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NVDA, ABNB, JNJ, TSLA, and MSFT. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of each...

Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2023. “Our first quarter results demonstrate strong performance across all three segments of our business and reflect the dedication of Johnson & Johnson colleagues around the world,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “With this momentum, I look forward to the remainder of the year, one filled with exciting catalysts that will create both near- and long-term value for patients and...

Thinking about buying stock in Nio, Spotify, Johnson & Johnson, Costco, or Boeing? PR Newswire NEW YORK, April 14, 2023 NEW YORK , April 14, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, SPOT, JNJ, COST, and BA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. NIO: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=NIO&prnumber=041420235...

...